With $30M, Octant Launches Synthetic Bio Search for Multi-Target Drugs

Octant, a new drug discovery company, launched Wednesday with millions in backing from tech investors to push ahead plans to leverage advances in science and in tech—including genomics, synthetic biology, and big data computation—to map out the relationships between chemicals, drug receptors, and diseases.